Genetic determinants of response to statins

References

• Cheung BM, Lauder IJ, Lau CP, Kumana CR. Meta-analysis of large randomized controlled trials to evaluate the impact of statins on cardiovascular outcomes. Br. J. Clin. Pharmacol.57(5), 640–651 (2004).
   PubMed Web of Science ®Google Scholar
• Chasman DI, Posada D, Subrahmanyan L, Cook NR, Stanton VP Jr, Ridker PM. Pharmacogenetic study of statin therapy and cholesterol reduction. JAMA291(23), 2821–2827 (2004).
   PubMed Web of Science ®Google Scholar
• Thompson JF, Man M, Johnson KJ et al. An association study of 43 SNPs in 16 candidate genes with atorvastatin response. Pharmacogenomics J.5(6), 352–358 (2005).
   PubMed Web of Science ®Google Scholar
• Donnelly LA, Doney AS, Dannfald J et al. A paucimorphic variant in the HMG-CoA reductase gene is associated with lipid-lowering response to statin treatment in diabetes: a GoDARTS study. Pharmacogenet. Genomics18(12), 1021–1026 (2008).
   PubMed Web of Science ®Google Scholar
• Kraus SR, Markland A, Chai TC et al. Race and ethnicity do not contribute to differences in preoperative urinary incontinence severity or symptom bother in women who undergo stress incontinence surgery. Am. J. Obstet. Gynecol.197(1), 92.e1–92.e6 (2007).
   Google Scholar
• Polisecki E, Muallem H, Maeda N et al. Genetic variation at the LDL receptor and HMG-CoA reductase gene loci, lipid levels, statin response, and cardiovascular disease incidence in PROSPER. Atherosclerosis200(1), 109–114 (2008).
   PubMed Web of Science ®Google Scholar
• Hindorff LA, Lemaitre RN, Smith NL et al. Common genetic variation in six lipid-related and statin-related genes, statin use and risk of incident nonfatal myocardial infarction and stroke. Pharmacogenet. Genomics18(8), 677–682 (2008).
   PubMed Web of Science ®Google Scholar
• Medina MW, Gao F, Ruan W, Rotter JI, Krauss RM. Alternative splicing of 3-hydroxy-3-methylglutaryl coenzyme A reductase is associated with plasma low-density lipoprotein cholesterol response to simvastatin. Circulation118(4), 355–362 (2008).
   PubMed Web of Science ®Google Scholar
• Ordovas JM, Lopez-Miranda J, Perez-Jimenez F et al. Effect of apolipoprotein E and A-IV phenotypes on the low density lipoprotein response to HMG CoA reductase inhibitor therapy. Atherosclerosis113(2), 157–166 (1995).
   PubMed Web of Science ®Google Scholar
• Ye P, Shang Y, Ding X. The influence of apolipoprotein B and E gene polymorphisms on the response to simvastatin therapy in patients with hyperlipidemia. Chin. Med. Sci. J.18(1), 9–13 (2003).
   PubMedGoogle Scholar
• Pedro-Botet J, Schaefer EJ, Bakker-Arkema RG et al. Apolipoprotein E genotype affects plasma lipid response to atorvastatin in a gender specific manner. Atherosclerosis158(1), 183–193 (2001).
   PubMed Web of Science ®Google Scholar
• Ballantyne CM, Herd JA, Stein EA et al. Apolipoprotein E genotypes and response of plasma lipids and progression-regression of coronary atherosclerosis to lipid-lowering drug therapy. J. Am. Coll. Cardiol.36(5), 1572–1578 (2000).
   PubMed Web of Science ®Google Scholar
• Nestel P, Simons L, Barter P et al. A comparative study of the efficacy of simvastatin and gemfibrozil in combined hyperlipoproteinemia: prediction of response by baseline lipids, apo E genotype, lipoprotein (a) and insulin. Atherosclerosis129(2), 231–239 (1997).
   PubMed Web of Science ®Google Scholar
• Takane H, Miyata M, Burioka N et al. Pharmacogenetic determinants of variability in lipid-lowering response to pravastatin therapy. J. Hum. Genet.51(9), 822–826 (2006).
   PubMed Web of Science ®Google Scholar
• Ojala JP, Helve E, Ehnholm C, Aalto-Setala K, Kontula KK, Tikkanen MJ. Effect of apolipoprotein E polymorphism and XbaI polymorphism of apolipoprotein B on response to lovastatin treatment in familial and non-familial hypercholesterolaemia. J. Intern. Med.230(5), 397–405 (1991).
   PubMed Web of Science ®Google Scholar
• Donnelly LA, Palmer CN, Whitley AL et al. Apolipoprotein E genotypes are associated with lipid-lowering responses to statin treatment in diabetes: a Go-DARTS study. Pharmacogenet. Genomics18(4), 279–287 (2008).
   PubMed Web of Science ®Google Scholar
• Pena R, Lahoz C, Mostaza JM et al. Effect of apoE genotype on the hypolipidaemic response to pravastatin in an outpatient setting. J. Intern. Med.251(6), 518–525 (2002).
   PubMed Web of Science ®Google Scholar
• Sanllehy C, Casals E, Rodriguez-Villar C et al. Lack of interaction of apolipoprotein E phenotype with the lipoprotein response to lovastatin or gemfibrozil in patients with primary hypercholesterolemia. Metabolism47(5), 560–565 (1998).
   PubMed Web of Science ®Google Scholar
• Tavintharan S, Lim SC, Chan YH, Sum CF. Apolipoprotein E genotype affects the response to lipid-lowering therapy in Chinese patients with Type 2 diabetes mellitus. Diabetes Obes. Metab.9(1), 81–86 (2007).
   PubMed Web of Science ®Google Scholar
• Zuccaro P, Mombelli G, Calabresi L, Baldassarre D, Palmi I, Sirtori CR. Tolerability of statins is not linked to CYP450 polymorphisms, but reduced CYP2D6 metabolism improves cholesteraemic response to simvastatin and fluvastatin. Pharmacol. Res.55(4), 310–317 (2007).
   PubMed Web of Science ®Google Scholar
• Maitland-van der Zee AH, Jukema JW, Zwinderman AH et al. Apolipoprotein-E polymorphism and response to pravastatin in men with coronary artery disease (REGRESS). Acta Cardiol.61(3), 327–331 (2006).
   PubMed Web of Science ®Google Scholar
• Fiegenbaum M, da Silveira FR, Van der Sand CR et al. Pharmacogenetic study of apolipoprotein E, cholesteryl ester transfer protein and hepatic lipase genes and simvastatin therapy in Brazilian subjects. Clin. Chim. Acta362(1–2), 182–188 (2005).
   PubMed Web of Science ®Google Scholar
• Gerdes LU, Gerdes C, Kervinen K et al. The apolipoprotein ε4 allele determines prognosis and the effect on prognosis of simvastatin in survivors of myocardial infarction : a substudy of the Scandinavian simvastatin survival study. Circulation101(12), 1366–1371 (2000).
   PubMed Web of Science ®Google Scholar
• Chiodini BD, Franzosi MG, Barlera S et al. Apolipoprotein E polymorphisms influence effect of pravastatin on survival after myocardial infarction in a Mediterranean population: the GISSI-Prevenzione study. Eur. Heart J.28(16), 1977–1983 (2007).
   PubMed Web of Science ®Google Scholar
• Maitland-van der Zee AH, Stricker BH, Klungel OH et al. The effectiveness of hydroxy-methylglutaryl coenzyme A reductase inhibitors (statins) in the elderly is not influenced by apolipoprotein E genotype. Pharmacogenetics12(8), 647–653 (2002).
   PubMedGoogle Scholar
• Maitland-van der Zee AH, Stricker BH, Klungel OH et al. Adherence to and dosing of β-hydroxy-β-methylglutaryl coenzyme A reductase inhibitors in the general population differs according to apolipoprotein E-genotypes. Pharmacogenetics13(4), 219–223 (2003).
   PubMedGoogle Scholar
• Mangravite LM, Krauss RM. Pharmacogenomics of statin response. Curr. Opin. Lipidol.18(4), 409–414 (2007).
   PubMed Web of Science ®Google Scholar
• Mangravite LM, Thorn CF, Krauss RM. Clinical implications of pharmacogenomics of statin treatment. Pharmacogenomics J.6(6), 360–374 (2006).
   PubMed Web of Science ®Google Scholar
• Choumerianou DM, Dedoussis GV. Familial hypercholesterolemia and response to statin therapy according to LDLR genetic background. Clin. Chem. Lab. Med.43(8), 793–801 (2005).
   PubMed Web of Science ®Google Scholar
• Lahoz C, Pena R, Mostaza JM et al. Baseline levels of low-density lipoprotein cholesterol and lipoprotein (a) and the AvaII polymorphism of the low-density lipoprotein receptor gene influence the response of low-density lipoprotein cholesterol to pravastatin treatment. Metabolism54(6), 741–747 (2005).
   PubMed Web of Science ®Google Scholar
• Salazar LA, Hirata MH, Quintao EC, Hirata RD. Lipid-lowering response of the HMG-CoA reductase inhibitor fluvastatin is influenced by polymorphisms in the low-density lipoprotein receptor gene in Brazilian patients with primary hypercholesterolemia. J. Clin. Lab. Anal.14(3), 125–131 (2000).
   PubMed Web of Science ®Google Scholar
• Hannuksela ML, Liinamaa MJ, Kesaniemi YA, Savolainen MJ. Relation of polymorphisms in the cholesteryl ester transfer protein gene to transfer protein activity and plasma lipoprotein levels in alcohol drinkers. Atherosclerosis110(1), 35–44 (1994).
   PubMed Web of Science ®Google Scholar
• Kuivenhoven JA, Jukema JW, Zwinderman AH et al. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. The Regression Growth Evaluation Statin Study Group. N. Engl. J. Med.338(2), 86–93 (1998).
   PubMed Web of Science ®Google Scholar
• Regieli JJ, Jukema JW, Grobbee DE et al. CETP genotype predicts increased mortality in statin-treated men with proven cardiovascular disease: an adverse pharmacogenetic interaction. Eur. Heart J.29(22), 2792–2799 (2008).
   PubMed Web of Science ®Google Scholar
• de Grooth GJ, Zerba KE, Huang SP et al. The cholesteryl ester transfer protein (CETP) TaqIB polymorphism in the cholesterol and recurrent events study: no interaction with the response to pravastatin therapy and no effects on cardiovascular outcome: a prospective analysis of the CETP TaqIB polymorphism on cardiovascular outcome and interaction with cholesterol-lowering therapy. J. Am. Coll. Cardiol.43(5), 854–857 (2004).
   PubMed Web of Science ®Google Scholar
• Freeman DJ, Samani NJ, Wilson V et al. A polymorphism of the cholesteryl ester transfer protein gene predicts cardiovascular events in non-smokers in the West of Scotland Coronary Prevention Study. Eur. Heart J.24(20), 1833–1842 (2003).
   PubMed Web of Science ®Google Scholar
• Klerkx AH, de Grooth GJ, Zwinderman AH, Jukema JW, Kuivenhoven JA, Kastelein JJ. Cholesteryl ester transfer protein concentration is associated with progression of atherosclerosis and response to pravastatin in men with coronary artery disease (REGRESS). Eur. J. Clin. Invest.34(1), 21–28 (2004).
   PubMed Web of Science ®Google Scholar
• Marschang P, Sandhofer A, Ritsch A, Fiser I, Kvas E, Patsch JR. Plasma cholesteryl ester transfer protein concentrations predict cardiovascular events in patients with coronary artery disease treated with pravastatin. J. Intern. Med.260(2), 151–159 (2006).
   PubMed Web of Science ®Google Scholar
• Carlquist JF, Muhlestein JB, Horne BD et al. The cholesteryl ester transfer protein Taq1B gene polymorphism predicts clinical benefit of statin therapy in patients with significant coronary artery disease. Am. Heart J.146(6), 1007–1014 (2003).
   PubMed Web of Science ®Google Scholar
• Boekholdt SM, Sacks FM, Jukema JW et al. Cholesteryl ester transfer protein TaqIB variant, high-density lipoprotein cholesterol levels, cardiovascular risk, and efficacy of pravastatin treatment: individual patient meta-analysis of 13,677 subjects. Circulation111(3), 278–287 (2005).
   PubMed Web of Science ®Google Scholar
• Sing K, Ballantyne CM, Ferlic L et al. Lipoprotein lipase gene mutations, plasma lipid levels, progression/regression of coronary atherosclerosis, response to therapy, and future clinical events. Lipoproteins and Coronary Atherosclerosis Study. Atherosclerosis144(2), 435–442 (1999).
   PubMed Web of Science ®Google Scholar
• Lahoz C, Pena R, Mostaza JM et al. The -514C/T polymorphism of the hepatic lipase gene significantly modulates the HDL-cholesterol response to statin treatment. Atherosclerosis182(1), 129–134 (2005).
   PubMed Web of Science ®Google Scholar
• Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N. Engl. J. Med.352(16), 1685–1695 (2005).
   PubMed Web of Science ®Google Scholar
• Jain MK, Ridker PM. Anti-inflammatory effects of statins: clinical evidence and basic mechanisms. Nat. Drug Discov.4(12), 977–987 (2005).
   PubMed Web of Science ®Google Scholar
• Iakoubova OA, Tong CH, Rowland CM et al. Association of the Trp719Arg polymorphism in kinesin-like protein 6 with myocardial infarction and coronary heart disease in 2 prospective trials: the CARE and WOSCOPS trials. J. Am. Coll. Cardiol.51(4), 435–443 (2008).
   PubMed Web of Science ®Google Scholar
• Bare LA, Morrison AC, Rowland CM et al. Five common gene variants identify elevated genetic risk for coronary heart disease. Genet. Med.9(10), 682–689 (2007).
   PubMed Web of Science ®Google Scholar
• Shiffman D, Chasman DI, Zee RY et al. A kinesin family member 6 variant is associated with coronary heart disease in the Women’s Health Study. J. Am. Coll. Cardiol.51(4), 444–448 (2008).
   PubMed Web of Science ®Google Scholar
• Shiffman D, O’Meara ES, Bare LA et al. Association of gene variants with incident myocardial infarction in the Cardiovascular Health Study. Arterioscler. Thromb. Vasc. Biol.28(1), 173–179 (2008).
   PubMed Web of Science ®Google Scholar
• Iakoubova OA, Sabatine MS, Rowland CM et al. Polymorphism in KIF6 gene and benefit from statins after acute coronary syndromes: results from the PROVE IT-TIMI 22 study. J. Am. Coll. Cardiol.51(4), 449–455 (2008).
   PubMed Web of Science ®Google Scholar
• Boekholdt SM, Agema WR, Peters RJ et al. Variants of Toll-like receptor 4 modify the efficacy of statin therapy and the risk of cardiovascular events. Circulation107(19), 2416–2421 (2003).
   PubMed Web of Science ®Google Scholar
• Holloway JW, Yang IA, Ye S. Variation in the Toll-like receptor 4 gene and susceptibility to myocardial infarction. Pharmacogenet. Genomics15(1), 15–21 (2005).
   PubMedGoogle Scholar
• Pausova Z, Syme CA, Abarahamowicz M et al. A Common Variant of the FTO Gene Is Associated With Not Only Increased Adiposity but Also Elevated Blood Pressure in French Canadians. Circ. Cardiovasc. Genet.2, 260–269 (2009).
   PubMedGoogle Scholar
• Maitland-van der Zee AH, Peters BJM, Lynch AI et al. The effect of nine common polymorphisms in coagulation factor genes (F2, F5, F7, F12 and F13) on the effectiveness of pravastatin: The GenHAT Study. Pharmacogenet. Genomics19(5), 338–344 (2009).
   PubMed Web of Science ®Google Scholar
• Shitara Y, Sugiyama Y. Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacol. Ther.112(1), 71–105 (2006).
   PubMed Web of Science ®Google Scholar
• Kajinami K, Brousseau ME, Ordovas JM, Schaefer EJ. CYP3A4 genotypes and plasma lipoprotein levels before and after treatment with atorvastatin in primary hypercholesterolemia. Am. J. Cardiol.93(1), 104–107 (2004).
   PubMed Web of Science ®Google Scholar
• Wang A, Yu BN, Luo CH et al. Ile118Val genetic polymorphism of CYP3A4 and its effects on lipid-lowering efficacy of simvastatin in Chinese hyperlipidemic patients. Eur. J. Clin. Pharmacol.60(12), 843–848 (2005).
   PubMed Web of Science ®Google Scholar
• Fiegenbaum M, da Silveira FR, Van der Sand CR et al. The role of common variants of ABCB1, CYP3A4, and CYP3A5 genes in lipid-lowering efficacy and safety of simvastatin treatment. Clin. Pharmacol. Ther.78(5), 551–558 (2005).
   PubMed Web of Science ®Google Scholar
• Kim KA, Park PW, Lee OJ, Kang DK, Park JY. Effect of polymorphic CYP3A5 genotype on the single-dose simvastatin pharmacokinetics in healthy subjects. J. Clin. Pharmacol.47(1), 87–93 (2007).
   PubMed Web of Science ®Google Scholar
• Kivisto KT, Niemi M, Schaeffeler E et al. Lipid-lowering response to statins is affected by CYP3A5 polymorphism. Pharmacogenetics14(8), 523–525 (2004).
   PubMedGoogle Scholar
• Willrich MA, Hirata MH, Genvigir FD et al.CYP3A53A allele is associated with reduced lowering-lipid response to atorvastatin in individuals with hypercholesterolemia. Clin. Chim. Acta398(1–2), 15–20 (2008).
   PubMed Web of Science ®Google Scholar
• Konig J, Seithel A, Gradhand U, Fromm MF. Pharmacogenomics of human OATP transporters. Naunyn Schmiedebergs Arch. Pharmacol.372(6), 432–443 (2006).
   PubMed Web of Science ®Google Scholar
• Tachibana-Iimori R, Tabara Y, Kusuhara H et al. Effect of genetic polymorphism of OATP-C (SLCO1B1) on lipid-lowering response to HMG-CoA reductase inhibitors. Drug Metab. Pharmacokinet.19(5), 375–380 (2004).
   PubMedGoogle Scholar
• Zhang W, Chen BL, Ozdemir V et al.SLCO1B1521T→C functional genetic polymorphism and lipid-lowering efficacy of multiple-dose pravastatin in Chinese coronary heart disease patients. Br. J. Clin. Pharmacol.64(3), 346–352 (2007).
   PubMed Web of Science ®Google Scholar
• Igel M, Arnold KA, Niemi M et al. Impact of the SLCO1B1 polymorphism on the pharmacokinetics and lipid-lowering efficacy of multiple-dose pravastatin. Clin. Pharmacol. Ther.79(5), 419–426 (2006).
   PubMed Web of Science ®Google Scholar
• Niemi M, Neuvonen PJ, Hofmann U et al. Acute effects of pravastatin on cholesterol synthesis are associated with SLCO1B1 (encoding OATP1B1) haplotype *17. Pharmacogenet. Genomics15(5), 303–309 (2005).
   PubMed Web of Science ®Google Scholar
• Kim RB, Leake BF, Choo EF et al. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin. Pharmacol. Ther.70(2), 189–199 (2001).
   PubMed Web of Science ®Google Scholar
• Kimchi-Sarfaty C, Oh JM, Kim IW et al. A “silent” polymorphism in the MDR1 gene changes substrate specificity. Science315(5811), 525–528 (2007).
   PubMed Web of Science ®Google Scholar
• Keskitalo J, Kurkinen K, Neuvonen P, Niemi M. ABCB1 haplotypes differentially affect the pharmacokinetics of the acid and lactone forms of simvastatin and atorvastatin. Clin. Pharmacol. Ther.84(4), 457–461 (2008).
   PubMed Web of Science ®Google Scholar
• Kajinami K, Brousseau ME, Ordovas JM, Schaefer EJ. Polymorphisms in the multidrug resistance-1 (MDR1) gene influence the response to atorvastatin treatment in a gender-specific manner. Am. J. Cardiol.93(8), 1046–1050 (2004).
   PubMed Web of Science ®Google Scholar
• Vladutiu GD. Genetic predisposition to statin myopathy. Curr. Opin. Rheumatol.20(6), 648–655 (2008).
   PubMed Web of Science ®Google Scholar
• Niemi M, Schaeffeler E, Lang T et al. High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1). Pharmacogenetics14(7), 429–440 (2004).
   PubMedGoogle Scholar
• Pasanen MK, Neuvonen M, Neuvonen PJ, Niemi M. SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet. Genomics16(12), 873–879 (2006).
   PubMed Web of Science ®Google Scholar
• Link E, Parish S, Armitage J et al.SLCO1B1 variants and statin-induced myopathy – a genome-wide study. N. Engl. J. Med.359(8), 789–799 (2008).
   PubMed Web of Science ®Google Scholar
• McKinney BA, Reif DM, Ritchie MD, Moore JH. Machine learning for detecting gene–gene interactions: a review. Appl. Bioinformatics5(2), 77–88 (2006).
   PubMedGoogle Scholar
• Evans WE, Relling MV. Moving towards individualized medicine with pharmacogenomics. Nature429(6990), 464–468 (2004).
   PubMed Web of Science ®Google Scholar